Visiting scientists to the Open Lab often cite access to world-class facilities and the opportunity
to work with scientists who work in the drug discovery field as the key benefits
of the Open Labs unique approach.
From its home at the Tres Cantos Medicines Development Campus, the Open Lab gives
visiting scientists access to GlaxoSmithKline drug discovery, pre-clinical expertise,
capabilities and the benefits of working as part of a project team.
This bold and flexible approach has positioned the Open Lab as a dynamic research
hub for diseases of the developing world, helping to stimulate innovative research
that could ultimately result in the discovery and development of new medicines.
The Open Lab provides access to:
- Biosafety Level 3 in vitro and in vivo laboratories which are used
as research or production facilities where work is conducted with pathogens that
may cause serious or potentially lethal diseases after inhalation, including TB.
The laboratories have special engineering and design features to ensure full decontamination.
Laboratory personnel have specific training in handling pathogenic and potentially
- The Drug Performance Units (DPUs) which are focused on malaria, TB and
Kinetoplastids are independent but coordinated units equipped with all the human
and technical resources needed to effectively address the challenges of each disease.
- GSKs ultra high-throughput world-class screening (uHTS) facility
specialises in identifying chemical starting points for drug discovery activities.
- The uHTS offers Open Lab scientists new opportunities to apply cutting-edge science
and technology in lead discovery and compound profiling including assay development,
HTS, computational chemistry, data analysis, IT and cell culture.
- These screening facilities are of huge importance in the initial stages of drug
discovery. Automated and robotic systems have been installed for chemical compound
management, to perform high throughput screening tests and also to culture cells.
These facilities are one of the most advanced in the pharmaceutical industry, with
a capacity to perform hundreds of thousands of biochemical and cellular experiments
- The facilities offer a large degree of flexibility to accommodate a variety of technologies
and assay types. Different screening strategies approaches are integrated, such
as HTS of focused sets, fragment-based lead discovery, knowledge-based screening
and comprehensive compound profiling of biological liabilities.
- GSKs complete compound screening library currently stands at more than two million
compounds. The collection of chemical products is located in an automated compound
store with a capacity for about 2.2 million individual samples.
The combination of these facilities and expertise enables this DDW centre to take
care of all scientific phases of drug discovery and development from screening campaigns
to clinical Proof of Concept studies. (Phase IIb)